C4’s Cemsidomide Data Supports Best-in-Class Myeloma Drug
C4 Therapeutics reported a 50% overall response rate at 100 µg and 40% at 75 µg for cemsidomide plus...
eClinical Tech News
SKYE Presents New Phase 1b Nimacimab Data at EASD Meeting
No serious adverse events, no discontinuations due to adverse events, and no neuropsychiatric safety signals were observed in a...
PDS Biotech Breakthrough Extends Head & Neck Cancer Survival
In a Phase 2 sub-analysis of HPV16-positive first-line recurrent or metastatic head and neck squamous cell carcinoma with low...
Intellia Completes Enrollment for Phase 3 HAE Drug Study
Enrollment in Intellia’s global Phase 3 HAELO trial for lonvoguran ziclomeran (lonvo-z; NTLA-2002) is complete nine months after first...
FDA Fast Track: A Breakthrough for Minovia’s MDS Drug MNV-201
FDA granted Fast Track designation to Minovia’s autologous mitochondrial cell therapy MNV-201 for myelodysplastic syndromes, adding a second expedited...
Sarcoidosis Foundation Reacts to Atyr Phase 3 Trial Results
In a 268‑patient Phase 3 trial spanning the U.S., Europe, Japan, and Brazil, efzofitimod did not meet its primary...
Cariprazine Depot Phase I/II Study Recruits First Patient
Mapi Pharma has enrolled the first patient in a multinational Phase I/II study of its once-monthly injectable cariprazine for...
World’s First Self-Regulating Immunotherapy Trial Launches
The UK’s MHRA has granted Clinical Trial Authorisation for NVG-222, clearing a first-in-human, Phase I/II adaptive basket study in...
Tonix Licenses Phase 2/3-Ready Antibody for Lyme Prevention
Phase 1 data for TNX-4800 (mAb 2217LS) showed safety and tolerability with a linear pharmacokinetic:pharmacodynamic: efficacy relationship, supporting dose...
Hope for AMD: Kalaris Enrolling New Phase 1/2 Drug Trial
No efficacy or safety data were released. Kalaris has begun enrolling a Phase 1b/2 multiple ascending dose study of...